Trial by CCN2: A standardized test for fibroproliferative disease?

Journal of Cell Communication and Signaling

Volumn 3, Issue 1, 2009, Pages 87-88

  Leask, Andrew ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

CCN2; CTGF

Indexed keywords

BIOLOGICAL MARKER; CONNECTIVE TISSUE GROWTH FACTOR; VASCULOTROPIN;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ARTICLE; BLINDNESS; CHRONIC DISEASE; DIABETIC RETINOPATHY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROPROLIFERATIVE DISEASE; FIBROSIS; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; STANDARDIZATION;

EID: 67349253030     PISSN: 18739601     EISSN: 1873961X     Source Type: Journal    
DOI: 10.1007/s12079-009-0041-y     Document Type: Article

References (4)

1. Blom IE, Goldschmeding R, Leask A (2002) Gene regulation of CTGF: New targets for antifibrotic therapy? Matrix Biol 21:473-482. doi: 10.1016/ S0945-053X(02) 00055-0
2. Fong DS, Aiello LP, Ferris FL 3rd, Klein R (2004) Diabetic retinopathy. Diabetes Care 27:2540-2553. doi: 10.2337/diacare.27.10.2540
3. Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, van Meurs JC, Tanck MW, Oliver N, Klaassen I, Van Noorden CJ, Goldschmeding R, Schlingemann RO (2008) The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One 3(7):e2675. doi: 10.1371/ journal.pone.0002675
4. Leask A, Parapuram SK, Shiwen X Abraham DJ (2009). Connective tissue growth factor (CTGF, CCN2) gene expression: A potent clinical marker of fibroproliferative disease. J. Cell Commun Signal., epub